Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

OBJECTIVES: ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adali...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Rheum Dis
Auteurs principaux: Cohen, Stanley, Genovese, Mark C, Choy, Ernest, Perez-Ruiz, Fernando, Matsumoto, Alan, Pavelka, Karel, Pablos, Jose L, Rizzo, Warren, Hrycaj, Pawel, Zhang, Nan, Shergy, William, Kaur, Primal
Format: Artigo
Langue:Inglês
Publié: Annals of the Rheumatic Diseases 2017
Sujets:
Clinical and Epidemiological Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5629940/
https://ncbi.nlm.nih.gov/pubmed/28584187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-210459
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires